Phase 1 study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies

BACKGROUND: The novel bispecific ligand-directed toxin (BLT) DT2219 consists of a recombinant fusion between the catalytic and translocation enhancing domain of diphtheria toxin (DT) and bispecific single chain variable fragments (scFV) of antibodies targeting human CD19 and CD22. We conducted a pha...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Bachanova, Veronika, Frankel, Arthur E., Cao, Qing, Lewis, Dixie, Grzywacz, Bartosz, Verneris, Michael R., Ustun, Celalettin, Lazaryan, Aleksandr, McClune, Brian, Warlick, Erica D., Kantarjian, Hagop, Weisdorf, Daniel J., Miller, Jeffrey S., Vallera, Daniel A.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4360883/
https://ncbi.nlm.nih.gov/pubmed/25770294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2877
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars